NGNE

Healthcare Biotechnology

Neurogene Inc.

$26.47

+1.16 +4.58% today

Price History

Not enough data

Key Stats

Market Cap

529.70M

Avg Volume

261,996

EPS

-$5.04

52W High

$43.66

52W Low

$15.93

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-5.11

P/B Ratio

1.93

EV/EBITDA

-2.65

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(45.3%)

Return on Assets

(28.0%)

Liquidity & Leverage

Current Ratio

10.64

Quick Ratio

10.50

Debt / Equity

0.04

Total Cash

225.39M

Total Debt

8.35M

About

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.